Impacts of Subtype on Clinical Feature and Outcome of Male Breast Cancer: Multicenter Study in Korea (KCSG BR16-09)
Cancer Res Treat. 2022 Mar 24.
DOI: 10.4143/crt.2021.1561.
Long-term outcomes in patients with advanced and/or metastatic non-small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU20-11)
Cancer. 2022 Feb 15;128(4):778-787.
DOI: 10.1002/cncr.33984.
Characteristics and treatment patterns in older patients with locally advanced head and neck cancer (KCSG HN13-01)
Korean J Intern Med. 2022 Jan;37(1):190-200.
DOI: 10.3904/kjim.2020.636.
Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16)
Gastric Cancer. 2022 May;25(3):609-618.
Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group
Cancer Res Treat. 2022 Jan;54(1):1-9.